{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T20:28:12Z","timestamp":1790368092654,"version":"4.1.0"},"reference-count":19,"publisher":"BMJ","issue":"8","license":[{"start":{"date-parts":[[2020,4,28]],"date-time":"2020-04-28T00:00:00Z","timestamp":1588032000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/L016311\/1"],"award-info":[{"award-number":["MR\/L016311\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["209553\/Z\/17\/Z."],"award-info":[{"award-number":["209553\/Z\/17\/Z."]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Thorax"],"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:sec><jats:title>Aims<\/jats:title><jats:p>Patients with idiopathic pulmonary fibrosis (IPF) receiving antifibrotic medication and patients with non-IPF fibrosing lung disease often demonstrate rates of annualised forced vital capacity (FVC) decline within the range of measurement variation (5.0%\u20139.9%). We examined whether change in visual CT variables could help confirm whether marginal FVC declines represented genuine clinical deterioration rather than measurement noise.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In two IPF cohorts (cohort 1: n=103, cohort 2: n=108), separate pairs of radiologists scored paired volumetric CTs (acquired between 6 and 24 months from baseline). Change in interstitial lung disease, honeycombing, reticulation, ground-glass opacity extents and traction bronchiectasis severity was evaluated using a 5-point scale, with mortality prediction analysed using univariable and multivariable Cox regression analyses. Both IPF populations were then combined to determine whether change in CT variables could predict mortality in patients with marginal FVC declines.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>On univariate analysis, change in all CT variables except ground-glass opacity predicted mortality in both cohorts. On multivariate analysis adjusted for patient age, gender, antifibrotic use and baseline disease severity (diffusing capacity for carbon monoxide), change in traction bronchiectasis severity predicted mortality independent of FVC decline. Change in traction bronchiectasis severity demonstrated good interobserver agreement among both scorer pairs. Across all study patients with marginal FVC declines, change in traction bronchiectasis severity independently predicted mortality and identified more patients with deterioration than change in honeycombing extent.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Change in traction bronchiectasis severity is a measure of disease progression that could be used to help resolve the clinical importance of marginal FVC declines.<\/jats:p><\/jats:sec>","DOI":"10.1136\/thoraxjnl-2019-213865","type":"journal-article","created":{"date-parts":[[2020,4,28]],"date-time":"2020-04-28T21:25:53Z","timestamp":1588109153000},"page":"648-654","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":46,"title":["Serial CT analysis in idiopathic pulmonary fibrosis: comparison of visual features that determine patient outcome"],"prefix":"10.1136","volume":"75","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8054-2293","authenticated-orcid":false,"given":"Joseph","family":"Jacob","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leon","family":"Aksman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nesrin","family":"Mogulkoc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex J","family":"Procter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahareh","family":"Gholipour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Cross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Barnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8302-702X","authenticated-orcid":false,"given":"Christopher J","family":"Brereton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6308-6014","authenticated-orcid":false,"given":"Mark G","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coline H","family":"van Moorsel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wouter","family":"van Es","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frouke","family":"van Beek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Veltkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujal R","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eoin","family":"Judge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Burd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Kokosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Recep","family":"Savas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selen","family":"Bayraktaroglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre","family":"Altmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athol U","family":"Wells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,4,28]]},"reference":[{"key":"2020100610200626000_75.8.648.1","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","article-title":"Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis","volume":"370","author":"Richeldi","year":"2014","journal-title":"N Engl J Med Overseas Ed"},{"key":"2020100610200626000_75.8.648.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402582"},{"key":"2020100610200626000_75.8.648.3","doi-asserted-by":"crossref","unstructured":"Flaherty KR , Brown KK , Wells AU , et al . Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease. BMJ Open Respir Res 2017;4:e000212. doi:10.1136\/bmjresp-2017-000212","DOI":"10.1136\/bmjresp-2017-000212"},{"key":"2020100610200626000_75.8.648.4","doi-asserted-by":"crossref","unstructured":"Maher TM , Corte TJ , Fischer A , et al . Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: design of a double-blind, randomised, placebo-controlled phase II trial. BMJ Open Respir Res 2018;5:e000289. doi:10.1136\/bmjresp-2018-000289","DOI":"10.1136\/bmjresp-2018-000289"},{"key":"2020100610200626000_75.8.648.5","doi-asserted-by":"crossref","unstructured":"Jacob J , Bartholmai BJ , van Moorsel CHM , et al . Longitudinal prediction of outcome in idiopathic pulmonary fibrosis using automated CT analysis. Eur Respir J 2019;54:1802341. doi:10.1183\/13993003.02341-2018","DOI":"10.1183\/13993003.02341-2018"},{"key":"2020100610200626000_75.8.648.6","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.2009-040GL"},{"key":"2020100610200626000_75.8.648.7","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201807-1255ST"},{"key":"2020100610200626000_75.8.648.8","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2462070712"},{"key":"2020100610200626000_75.8.648.9","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1097\/RCT.0b013e3182277d05","article-title":"Method for minimizing observer variation for the quantitation of high-resolution computed tomographic signs of lung disease","volume":"35","author":"Sverzellati","year":"2011","journal-title":"J Comput Assist Tomogr"},{"key":"2020100610200626000_75.8.648.10","doi-asserted-by":"publisher","DOI":"10.1038\/sj.hdy.6800717"},{"key":"2020100610200626000_75.8.648.11","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200611-1696OC"},{"key":"2020100610200626000_75.8.648.12","doi-asserted-by":"crossref","unstructured":"Jacob J , Bartholmai BJ , Rajagopalan S , et al . Mortality prediction in idiopathic pulmonary fibrosis: evaluation of computer-based CT analysis with conventional severity measures. Eur Respir J 2017;49:1601011. doi:10.1183\/13993003.01011-2016","DOI":"10.1183\/13993003.01011-2016"},{"key":"2020100610200626000_75.8.648.13","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-012-2427-0"},{"key":"2020100610200626000_75.8.648.14","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2013-203843"},{"key":"2020100610200626000_75.8.648.15","doi-asserted-by":"crossref","unstructured":"Jacob J , Bartholmai BJ , Egashira R , et al . Chronic hypersensitivity pneumonitis: identification of key prognostic determinants using automated CT analysis. BMC Pulm Med 2017;17:81. doi:10.1186\/s12890-017-0418-2","DOI":"10.1186\/s12890-017-0418-2"},{"key":"2020100610200626000_75.8.648.16","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.rmed.2017.07.007","article-title":"Unclassifiable-interstitial lung disease: outcome prediction using CT and functional indices","volume":"130","author":"Jacob","year":"2017","journal-title":"Respir Med"},{"key":"2020100610200626000_75.8.648.17","doi-asserted-by":"crossref","unstructured":"Jacob J , Bartholmai BJ , Rajagopalan S , et al . Evaluation of computer-based computer tomography stratification against outcome models in connective tissue disease-related interstitial lung disease: a patient outcome study. BMC Med 2016;14:190. doi:10.1186\/s12916-016-0739-7","DOI":"10.1186\/s12916-016-0739-7"},{"key":"2020100610200626000_75.8.648.18","doi-asserted-by":"crossref","unstructured":"Jacob J , Hirani N , van Moorsel CHM , et al . Predicting outcomes in rheumatoid arthritis related interstitial lung disease. Eur Respir J 2019;53:1800869. doi:10.1183\/13993003.00869-2018","DOI":"10.1183\/13993003.00869-2018"},{"key":"2020100610200626000_75.8.648.19","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00692-2018"}],"container-title":["Thorax"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/thoraxjnl-2019-213865","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T17:22:10Z","timestamp":1602004930000},"score":1,"resource":{"primary":{"URL":"https:\/\/thorax.bmj.com\/lookup\/doi\/10.1136\/thoraxjnl-2019-213865"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,28]]},"references-count":19,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2020,7,15]]},"published-print":{"date-parts":[[2020,8]]}},"alternative-id":["10.1136\/thoraxjnl-2019-213865"],"URL":"https:\/\/doi.org\/10.1136\/thoraxjnl-2019-213865","relation":{},"ISSN":["0040-6376","1468-3296"],"issn-type":[{"value":"0040-6376","type":"print"},{"value":"1468-3296","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,28]]}}}